GAITHERSBURG, Md., Feb. 21,
2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a
global vaccines company advancing protein-based vaccines with
its novel Matrix-M™ adjuvant, today announced it will report its
fourth quarter and full year 2022 financial results and operational
highlights on Tuesday, February 28,
2023, following the close of U.S. financial markets. Details
of the event and replay are as follows:
|
Conference call
details:
|
|
|
Date:
|
February 28,
2023
|
|
Time:
|
4:30 p.m. U.S. Eastern
Standard Time (EST)
|
|
Dial-in
number:
|
(833) 974-2381
(Domestic) or (412) 317-5774 (International)
|
|
Webcast:
|
ir.novavax.com/events
|
- Participants will be prompted to request to join the
Novavax, Inc. call.
- To ensure a timely connection, it is recommended that
participants join at least 10 minutes prior to the scheduled
webcast.
|
Replay
details:
|
|
Date:
|
Available starting at
7:30 p.m. EST, February 28, 2023 until 11:59 p.m. U.S. EST, March
7, 2023
|
|
Dial-in
number:
|
(877) 344-7529
(Domestic) or (412) 317-0088 (International)
|
|
Passcode:
|
1137418
|
|
Webcast:
|
ir.novavax.com/events,
until May 28, 2023
|
About Novavax
Novavax, Inc. (Nasdaq: NVAX)
promotes improved health by discovering, developing and
commercializing innovative vaccines to protect against serious
infectious diseases. Novavax, a global company based in
Gaithersburg, Md., U.S., offers a
differentiated vaccine platform that combines a recombinant protein
approach, innovative nanoparticle technology and Novavax's patented
Matrix-M adjuvant to enhance the immune response. Focused on the
world's most urgent health challenges, Novavax is currently
evaluating vaccines for COVID-19, influenza, and COVID-19 and
influenza combined. Please visit novavax.com and
LinkedIn for more information.
CONTACTS
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2022-financial-results-and-operational-highlights-on-february-28-2023-301751345.html
SOURCE Novavax, Inc.